Imatinib for COVID-19: A case report

Clin Immunol. 2020 Sep:218:108518. doi: 10.1016/j.clim.2020.108518. Epub 2020 Jun 27.
No abstract available

Keywords: ABL kinase inhibitor; COVID-19; Imatinib; SARS-CoV-2; Treatment.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Betacoronavirus / pathogenicity*
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • COVID-19
  • Coronavirus Infections / diagnostic imaging
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / pathology
  • Coronavirus Infections / virology
  • Drug Combinations
  • Female
  • Humans
  • Hydroxychloroquine / administration & dosage
  • Imatinib Mesylate / therapeutic use*
  • Lopinavir / administration & dosage
  • Lung / diagnostic imaging
  • Lung / drug effects*
  • Lung / pathology
  • Lung / virology
  • Pandemics
  • Pneumonia, Viral / diagnostic imaging
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / pathology
  • Pneumonia, Viral / virology
  • Protein Kinase Inhibitors / therapeutic use*
  • Ritonavir / administration & dosage
  • SARS-CoV-2
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Biomarkers
  • Drug Combinations
  • Protein Kinase Inhibitors
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Hydroxychloroquine
  • Imatinib Mesylate
  • C-Reactive Protein
  • Ritonavir